Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01889 (ankylosing spondylitis)
 5,717 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Highly significant improvement of symptoms was found during treatment with clofezone (Perclusone) over a period of 4 weeks in 56 in-patients with various rheumatic diseases, particularly rheumatoid arthritis (RA), ankylosing spondylitis (AS), and lumbar and cervical syndromes. During the first week clofezone was given at a daily dosage of 1200 mg and thereafter 600 mg. At the same time 21 of the patients with RA and 13 with AS received ACTH injections (0.25 mg twice a week). Already after the first week of treatment a highly significant decrease of disease activity was noticed, as judged by the amount of pain, inhibition of movements, joint swelling and erythrocyte sedimentation rate. The latter decreased on an average by 50% during the treatment period indicating a reduction of the inflammatory process. 51 of the 56 patients showed a satisfactory to very good tolerance of the treatment. Clofezone was discontinued in 5 patients during the first week, because gastro-intestinal intolerance occurred with the 1200 mg dosage. One of these 5 patients tolerated the smaller dosage later. As 3 of the 5 patients belonged to the RA and AS groups, the ACTH administration also has to be considered with regards to the intolerance. Because of possible side effects the higher dosage of clofezone should be given as short term treatment of highly active disease processes only. Clofezone reduced the serum uric acid level in 38 of 45 patients. Pathologically increased levels were reduced to normal in 15 of 17 patients.
 ...
PMID:[Experiences in the management of rheumatoid diseases using different clofezone doses]. 13 65

A comparative controlled study was carried out in 40 patients suffering from rheumatoid arthritis, osteoarthrosis or ankylosing spondylitis to assess the efficacy of ketoprofen and ibuprofen. Patients were allocated at random to receive either 100 mg ketoprofen twice daily or 400 mg ibuprofen 3-times daily over a period of 3 months. Subjective overall assessments of symptoms, based on rating scale scores for pain, duration of morning stiffness and inflammation, showed that there was a greater, more rapid and more sustained improvement in those patients treated with ketoprofen. Measurements of inflamed joint size and of grip strength also improved more with ketoprofen than with ibuprofen. Side-effects, notably nausea, epigastric discomfort and abdominal pain, were more frequent and severe with ketoprofen, leading to the withdrawal of 2 patients in the early stage of the trial, and were probably related to the high dosage used. Three patients receiving ibuprofen needed 7 injections of ACTH to control their symptoms.
 ...
PMID:A comparative trial of ketoprofen and ibuprofen in patients with rheumatic disease. 35 May

Fourteen male patients with ankylosing spondylitis, admitted for a 2-week period of inpatient treatment, had their spinal mobility assessed on admission and at the end of treatment by clinical measures and a three-dimensional radiographic technique. The patients were given injections of low-dose corticotrophin (ACTH) or placebo under a double-blind protocol. Initially all the patients had restricted movements compared with normal. After treatment all showed some improvement of mobility but no additional benefit accrued from ACTH. Clinical measures of mobility must be interpreted with care as the changes in these measurements were not closely reflected in the lumbar movements measured radiographically. Changes seen in plain radiographs were of little predictive value for improvements in mobility.
 ...
PMID:Spinal movements in ankylosing spondylitis and the effect of treatment. 299 56

Pro-inflammatory cytokines, such as interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF alpha), released from inflammatory foci, can activate the hypothalamus to produce corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP). These hypothalamic peptides in synergy increase ACTH production by the pituitary gland and hence corticosteroid (CS) secretion by the adrenal cortices. CS dampens inflammation. The pituitary also produces prolactin (PRL), which is pro-inflammatory, and macrophage inhibitory factor (MIF), which by counteracting the anti-inflammatory and immunosuppressive effects of CS, is pro-inflammatory. Lewis rats develop a variety of induced-autoimmune inflammatory conditions, such as streptococcal cell wall arthritis, whereas the histocompatible F344 Fisher rats are resistant to this condition. Lewis rats have a defective hypothalamic-pituitary adrenal (HPA) response to a variety of hypothalamic stimuli, but have augmented systemic secretion of AVP. Patients with rheumatoid arthritis (RA) have deficient CS with exaggerated PRL responses to inflammatory stimuli. Within inflammatory foci, CRH is pro-inflammatory. AVP, which augments autologous mixed lymphocyte reactions, can replace the IL-2 requirement for gamma IFN production by T cells via V1a receptors, and potentiates primary antibody responses, is also pro-inflammatory. Lewis rats have significantly high plasma levels, hypothalamic content, and in vitro release of AVP in comparison to the inflammatory disease-resistant Fischer rats. Immunoneutralization of AVP attenuates inflammatory responses. In Sprague-Dawley rats, AVP potentiates PRL secretion. Preliminary studies in patients with RA have shown that the circulating levels of AVP are significantly increased, which might be a compensatory response to low CS levels or a result of elevated levels of IL-6 in these patients but could nevertheless contribute to rheumatoid inflammation. A similar observation has been made in patients with ankylosing spondylitis.
 ...
PMID:Perturbations of arginine vasopressin secretion during inflammatory stress. Pathophysiologic implications. 1126 12